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This study was performed to investigate the usefulness of a
general-purpose medium-energy (ME) collimator for the accu-
rate localization of the sentinel lymph node (SLN) in breast
cancer patients. Methods: We compared phantom images and
lymphoscintigraphy images obtained under different conditions
for a patient with breast cancer. Comparisons were performed
between 2 cameras, between a low-energy high-resolution
(LEHR) collimator and a general-purpose ME collimator, and be-
tween energy windows centered at 141 keV and at 146 keV. Pro-
file curves and image contrast were evaluated along with the
visual interpretation of images. The most suitable imaging time
was selected from the relationship between contrast and the
data acquisition time. Results: The images obtained with the
general-purpose ME collimator and the energy window centered
at 141 keV were of poorer quality than those obtained with the
LEHR collimator and the same energy window. However, the
quality of the images obtained with the general-purpose ME col-
limator improved when the energy window was centered at 146
keV. The method involving the general-purpose ME collimator
and the energy window centered at 146 keV showed excellent
image quality similar to that obtained with the LEHR collimator.
The enhancement of contrast was confirmed at more than
3 cm away from the center of the injection site. Stable contrast
was obtained with a data acquisition time of 5 min, with the
general-purpose ME collimator, and with the energy window
centered at 146 keV. Conclusion: The method involving the
general-purpose ME collimator and the energy window centered
at 146 keV has the merit of the lymph node not being concealed
by a lead shield. This newmethod is expected to improve the rate
of detection of SLN and has the potential for shortening the ac-
quisition time.
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Since the introduction of the concept of radionuclide
sentinel lymph node (SLN) identification in the manage-
ment of melanoma, radionuclide sentinel node lympho-
scintigraphy has rapidly become an accepted means of
evaluating regional lymph node status for melanoma and
breast tumors (1–8). The advantages of radionuclide
lymphoscintigraphy over the blue dye method include ease
of injection, shorter time interval between injections, and
improved SLN detection (9). On the other hand, radionu-
clide lymphoscintigraphy has some disadvantages, partic-
ularly with breast node studies. The target tissues are small
and contain only a small amount of radioactivity. A large
amount of activity is retained at the injection site and can
cause artifacts through scatter or septal penetration (8).
The technique for lymphatic mapping is well established
for melanoma but not for breast cancer (7). Furthermore,
technique is very important for minimizing artifacts and
improving lesion detection during breast imaging (10–17).
Placing a small lead shield over the injection site has been
reported in the literature (9). However, the use of a lead
shield has the disadvantage that the lead shield may conceal
the SLN. To avoid the possibility of a lead shield conceal-
ing the SLN, we devised a new method using a medium-
energy (ME) collimator without a lead shield. We also tried
to adjust the center of the energy window because it was
reported that adjustment of the energy window might at
times assist in the imaging of lymph nodes that are close to
the injection site (1). We developed an imaging phantom
based on the clinical data and evaluated the usefulness of an
ME collimator for the accurate localization of SLNs in
breast cancer patients.
MATERIALS AND METHODS
Phantoms
To evaluate the usefulness of an ME collimator for sentinel
node lymphoscintigraphy in breast cancer patients, we used 3
types of phantoms made of acrylic plates. The first phantom, an
injection site phantom (IS phantom), was a cylindric source that
was 2 cm in diameter and 1 cm thick and contained 40 MBq of
Received Jul. 5, 2005; revision accepted May 15, 2006.
For correspondence or reprints contact: Hiroyuki Tsushima, PhD,
Department of Radiological Technology, Osaka City University Hospital,
1-5-7 Asahimachi, Abeno, Osaka 545-8586, Japan.
E-mail: tsushima@med.osaka-cu.ac.jp
COPYRIGHT ª 2006 by the Society of Nuclear Medicine Technology, Inc.
USEFULNESS OF ME COLLIMATOR FOR SLNS • Tsushima et al. 153
99mTc-pertechnetate. The second phantom, a lymph node phantom
(LN phantom), was made to estimate the effect of the concentra-
tion of radioactivity on image quality. The phantom was con-
structed of a 15 · 30 cm square plate that was 1 cm thick and
had 30 holes (Figs. 1A and 1C). The 30 holes were divided into
3 groups of 10 holes with diameters of 6.0, 8.5, and 12 mm
for groups 1, 2, and 3, respectively. The concentration of 99mTc-
pertechnetate in 10 holes was changed from 0.78 to 400 kBq/
200 mL in 1:2 increments over 10 steps so that the lymph node
image density might vary stepwise in accordance with the concen-
tration of radioactivity. The surface and the bottom of the acrylic
plate were covered with waterproof sheets to prevent the leakage
of radiopharmaceuticals. The third phantom, a combination phan-
tom (CB phantom), simulating both injection site and SLNs, was
used to study the effect of the distance from the injection site to
the lymph node on image quality. A lymph node was simulated by
40 kBq of 99mTc-pertechnetate placed in a hole in a 2 · 2 cm
square acrylic plate that was 1 cm thick. The measurements of the
simulated lymph node were 5 and 10 mm. As shown in Figure 1B,
a total of 12 plates with a hole were aligned 3, 5, and 7 cm from
the center of the IS phantom in both the horizontal (H) direction
and the oblique (S) direction; these directions were selected be-
cause they align with where one would expect to see star artifacts
resulting from septal penetration. Figure 1D shows an illustration
of this phantom.
Imaging
This study was performed with 2 dual-head g-cameras: a
FORTE (ADAC) and a DSX rectangular (Sopha Medical Corp.).
Standard imaging was performed with a FORTE camera because
that camera showed the best image quality. To study the effect of
radioactivity in the lymph nodes on image quality, the LN
phantom was imaged by use of the FORTE camera with a low-
energy (LE) high-resolution (LEHR) collimator and the energy
window centered at 141 keV (65%) for 250 s of data acquisition.
The image matrix was 256 · 256 (1 pixel 5 2.36 mm).
To compare the performances of the 2 cameras attached to an
LE collimator, the IS phantom was imaged. Before imaging, we
made 2 assumptions. One is that the attenuation and the scattering
of g-rays caused by a patient’s body are equal to the values for an
acrylic plate that is 20 cm thick. The other is that the SLNs in
breast cancer patients are located at a depth of 2 cm. On the basis
of these assumptions, the IS phantom was sandwiched between
2- and 18-cm acrylic plates. The images were obtained with the LE
collimator, with the energy window centered at 141 keV (65%),
and with or without a lead shield for 250 s of data acquisition. As
in clinical practice with an LE collimator and a lead shield (lead
shielding method), we used a lead shield that was 4 cm in
diameter and 3 mm thick. A lead shield was placed directly on the
phantom. The distance between the surface of the collimator and
the lead shield was 1 cm.
Next, we studied the effects of the collimators and the energy
window on image quality by imaging the CB phantom with an
LEHR collimator or an ME collimator and the 2 energy windows
centered at 141 and 146 keV (65%). On this occasion, we
excluded the evaluation of 146 keV for the LEHR collimator
because that value lengthened the data acquisition time for the
LEHR collimator as a result of the lower sensitivity of the LEHR
collimator than of the ME collimator. The sensitivity of the ME
collimator with the energy window centered at 146 keV (ME
method) was equal to that of the lead shielding method.
Finally, we also investigated the usefulness of an ME collimator
in patients with breast cancer. At 4 h after the peritumoral injection
of 40 MBq (1.5 mL) of 99mTc-tin colloid, an anterior image was
obtained for 250 s in the supine position by use of the FORTE
camera attached to an LEHR collimator or an ME collimator.
FIGURE 1. (A and C) Appearance and
illustration of LN phantom, respectively.
Holes were 8.5 mm (top row), 6.0 mm
(middle row), and 12.0 mm (bottom rows)
in diameter. Concentration of 99mTc-
pertechnetate in 10 holes with same
diameters was changed from 0.78 (right)
to 400 kBq (left) per 200 mL in 1:2
increments over 10 steps. (B and D)
Appearance and illustration of CB phan-
tom, respectively. Holes containing radi-
oactivity simulating lymph node were
placed at 3, 5, and 7 cm from center of
cylindric source. Band 1 and band 2
show regions for which profile curves
were obtained in H and S directions,
respectively. (E) Image of LN phantom
taken with LEHR collimator and energy
window centered at 141 keV. Note that
sizes of hot spots changed with concen-
tration of radioactivity.
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Profile Curves
Profile curves were drawn by plotting continuously the counts
in the regions of interest (ROIs) against the distance. As shown in
Figure 1D, the size of each ROI on the CB phantom image was
1 pixel (2.36 mm) in length and 4 pixels (9.4 mm) in width.
Counts were measured in the H and S directions, starting from the
center of the injection site on the CB phantom image.
Evaluation of Image Contrast
Both the IS phantom and the LN phantom were used to
determine contrast. The IS phantom was used to determine the
background by placing ROIs of 4 · 4 pixels in 1-cm increments at
2–7 cm from the center of the injection site. Corresponding ROIs
were placed on the LN phantom. Under such circumstances,
8.5-mm holes in the LN phantom were filled with 25, 100, and
400 kBq of the tracer. Contrast then was calculated with the
following equation:
C5 ðSLN2BGÞ=ðSLN1BGÞ; Eq. 1
where C represents contrast, SLN represents the mean counts in
the lymph node ROIs, and BG represents the background counts
in the IS regions. Because we cannot discriminate the true counts
included in the SLN from the BG counts, we used the BG counts ob-
tained from the IS regions and assumed that the BG counts in the
LN regions are equal to the values in the IS regions.
Using the values obtained for contrast, we evaluated the effects
of lymph node site on image quality and appropriate acquisition
time. To obtain the values for contrast at different data acquisition
times, each IS phantom and each LN phantom were imaged for
1–15 min at 1-min intervals. On the basis of the values obtained
from these images and Equation 1, the relationship between
contrast and data acquisition times was obtained, and the most
suitable time was selected.
RESULTS
Comparison of Images
Figure 1E shows an LN phantom image obtained with
the LEHR collimator and the energy window centered at
141 keV. It is noteworthy that the sizes of hot spots
decreased with a decrease in the concentration of radioac-
tivity in the lymph nodes. As shown in Figure 2, the IS
phantom image obtained with the FORTE camera and the
LEHR collimator clearly was superior to that obtained with
the DSX rectangular camera because the DSX rectangular
camera with a GAP2 collimator and with or without a lead
shield yielded prominent star-shaped artifacts.
The CB phantom image obtained with the ME collimator
and the energy window centered at 141 keV showed a larger
area of intense radioactivity and an increase in the surround-
ing background relative to the results obtained with the lead
shielding method (Fig. 3). However, when the center of the
energy window was shifted from 141 to 146 keV with the
same ME collimator, the image showed a smaller area of
intense radioactivity and a decrease in the background.
Generally, the DSX rectangular camera yielded more star-
shaped artifacts and a higher background around the area of
intense radioactivity than did the FORTE camera.
Figure 4 shows static sentinel node lymphoscintigraphy
(anterior views) in a patient with breast cancer. The star-
shaped artifact was not completely eliminated with the lead
shielding method. Therefore, there is a possibility of pro-
ducing a study with false-negative results when the lead
FIGURE 2. Comparison of IS phantom images obtained with 2
cameras. (A) FORTE camera without lead shield. (B) DSX
rectangular camera without lead shield. (C) FORTE camera with
lead shield. (D) DSX rectangular camera with lead shield.
Images were taken with LE collimator and energy window
centered at 141 keV (65%) for 250 s of data acquisition.
Prominent star-shaped artifacts are shown on DSX rectangular
camera images.
FIGURE 3. Comparison of CB phantom images obtained with
FORTE camera (A) and DSX rectangular camera (B). (Left) 141
keV with LE collimator and lead shield—central white area
shows effect of lead shield. (Middle) 141 keV with ME
collimator. (Right) 146 keV with ME collimator.
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shield does not cover the injection site. Even small SLNs
could be depicted more clearly when the ME method was
used than when an ME collimator with an energy window
centered at 141 keV was used.
Evaluation of Profile Curves
Figure 5 shows the profile curves acquired with the
FORTE and the DSX rectangular cameras. There was a
marked difference in counts detected between the g-cameras.
The latter yielded higher counts than the former, indicating
the greater sensitivity of the latter. The counts in the hot spots
(lymph nodes) at 5 cmwere higher than thevalues at 7 cm and
lower than the values at 3 cm, reflecting the amount of
scattering caused by the area of high radioactivity at the
injection site. For the FORTE camera, similar curves were
obtained with the lead shielding method and theMEmethod,
except at 2 cm, at which the former yielded lower counts
because of the lead shield. Furthermore, there was no
observed difference between the H and the S directions with
the MEmethod. (Therefore, we omit the distinction between
the H and the S directions in the ME method.) Similar
results were obtained with the 5-mm holes.
Evaluation of Image Contrast
As shown in Figure 6, contrast was greatly affected by
the radioactivity in the lymph nodes. Contrast increased
with increasing distance with radioactivity at 25 kBq,
whereas contrast attained a plateau with increasing distance
with radioactivity at 400 kBq. There was not such a marked
difference between the H-direction data and the S-direction
data. Contrast at 2 cm was lower with the ME method than
with the lead shielding method. However, contrast at more
than 3 cm was higher with the ME method than with the
lead shielding method. Contrast attained a value of 1.0 (i.e.,
zero count for the background) at more than 5 and 7 cm
with the ME method and the lead shielding method, re-
spectively.
Figure 7 shows the relationship between data acquisition
time and image contrast at 3 and 5 cm from the injection
site. At 3 cm (Figs. 7A and 7B), similar trends were
observed between the lead shielding method and the ME
method. However, at 5 cm (Figs. 7C and 7D), a difference
was observed between the methods. The ME method
yielded higher contrast than the lead shielding method,
even for the low level of radioactivity of 25 kBq, and
contrast became stable after 5 min. Thus, the use of the ME
method is expected to shorten the imaging time.
DISCUSSION
Phantoms
We made 3 types of phantoms based on the clinical data
obtained from 25 breast cancer patients in our hospital. The
FIGURE 4. Static sentinel node lym-
phoscintigraphy (anterior views) in pa-
tient with breast cancer. (A) Image
obtained with LEHR collimator and lead
shield (lead shielding method). Lead
shield covers imperfectly radioactivity at
injection site. (B) Image obtained with ME collimator and energy window centered at 141 keV. (C) Image obtained with ME
collimator and energy window centered at 146 keV (ME method). Arrows 1 and 2 show SLNs. ME method produced clear depiction
of even small SLN (arrow 1).
FIGURE 5. Profile curves acquired with
10-mm holes in CB phantom. (A and B)
FORTE camera curves. (C and D) DSX
rectangular camera curves. (A and C)
Lead shielding method. (B and D) ME
method. Note difference in longitudinal
scales between FORTE and DSX rectan-
gular camera graphs. Data obtained in H
direction and data obtained in S direction
are shown by plain solid line and by solid
line with circles, respectively.
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sizes of surgically excised SLNs ranged from 5 to 15 mm in
diameter. The radioactivity in the SLNs corresponded to
2 kBq–1.2 MBq, representing less than 3% of the total dose
of 40 MBq. These values were determined with the
regression equation for counts and radioactivities estimated
previously from LN phantoms (8.5-mm holes in Fig. 1C):
y 5 0.1162x (R2 5 0.998, P , 0.01), where y represents
counts (counts/pixel) and x represents the amount of radio-
activity (kBq). De Cicco et al. (6) reported that about 1% of
the injected dose is retained per node when the tracer is
injected subdermally into patients with breast cancer, with
much smaller amounts being retained (0.1% of the injected
dose per node) when the tracer is injected into the peri-
tumoral parenchyma. We also found that the distance from
the injection site to the SLN was 3.2–14.7 cm (7.5 6 2.7
[mean 6 SD] cm) on the lymphoscintigraphy anterior view
and 3.6–15.7 cm (10.1 6 2.9 cm) on the oblique view and
that every SLN was located more than 3 cm from the
injection site.
Comparison of Images
Previously, we reported that star-shaped artifacts ap-
peared symmetrically in certain oblique directions, depend-
ing greatly on penetration through collimators (16). For
example, as shown in Figure 2, star-shaped artifacts oc-
curred slightly on FORTE camera images, whereas marked
artifacts were observed on DSX rectangular camera images.
As shown in Figure 5, the DSX rectangular camera yielded
higher counts than the FORTE camera, reflecting its 1.6-
fold-greater sensitivity (the value of 1.6 [7.4/4.6] can be
obtained from the sensitivities of 7.4 and 4.6 cpm/kBq
when the LE collimator is used with the DSX rectangular
and FORTE cameras, respectively). Generally, LE colli-
mators cause variations in penetration, resulting in the
occurrence of star-shaped artifacts. The manufacturers
demonstrated that 5% penetration would be caused by
150-keV energy photons with the DSX rectangular camera
and 173-keV energy photons with the FORTE camera
despite the same septal thickness of 0.15 mm for the LE
collimator. In contrast, the septal thicknesses for the ME
collimator were 1.14 and 0.9 mm with the FORTE and
DSX rectangular cameras, respectively. Consequently, the
difference in septal thickness between the collimators with
the FORTE camera was 7.6-fold (1.14/0.15). This finding
suggested that the ME collimator might be useful for
decreasing the septal penetration of g-rays.
Mariani et al. (8) reported that scattering was a major
problem in the detection of an SLN located close to the
FIGURE 6. Relationship between
lymph node site (distance from injection
site) and image contrast with various
levels of radioactivity for 5 min of data
acquisition. (A) 25 kBq. (B) 100 kBq. (C)
400 kBq. Data obtained in H-direction
with lead shielding method, data obtained in S-direction with lead shielding method, and data obtained with ME method are
represented by plain thin line, by thin line with circles, and by thick line, respectively.
FIGURE 7. Relationship between im-
age contrast and data acquisition time.
(A) Contrast at 3 cm with lead shielding
method. (B) Contrast at 3 cm with ME
method. (C) Contrast at 5 cm with lead
shielding method. (D) Contrast at 5 cm
with ME method. Radioactivity concen-
trations of 400, 100, and 25 kBq/200 mL
are represented by plain solid line, by
dotted line, and by solid line with circles,
respectively.
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tumor. As star-shaped artifacts can impair the visualization
of nearby SLNs, it is desirable that they will be decreased
as much as possible. In the present study, the images obtained
with the ME collimator and the energy window centered at
141 keV showed a greater increase in the background than
did those obtained with the LE collimator because of
greater scattering. However, when the center of the energy
window was shifted upward by 5 keV, improved images
with less background were obtained. Krynyckyi et al. (13)
noted that excluding the lower energy window that is
contaminated with scattering information will generally
improve the quality of images. As reported byGlass et al. (1),
scattering can be reduced by sampling only the high side of
the photopeak, although doing so is achieved at the cost of
camera field uniformity and counting rate. However, the
degradation in uniformity with a digital g-camera can be
improved by correcting with a uniformity-corrected table in
which the energy level is coincident with the off-center
energy. Additionally, the decrease in counting rate can be
diminished with anME collimator with high sensitivity (16).
In this respect, uniformity is of less concern in lymphoscin-
tigraphy because the tracer is intensely concentrated in the
lymphatics and at the injection site (1).
Lemstra et al. (15) performed a comparison between LE
all-purpose (LEAP) and ME all-purpose (MEAP) collima-
tors for SLN detection in breast cancer patients by phantom
and clinical studies. In contrast to our results, they con-
cluded that the LEAP collimator yielded better results
than the MEAP collimator as a result of the better resolu-
tion and higher sensitivity. There were several differences
between their study and our study. First, they used an LEAP
collimator with a sensitivity 7% higher and a spatial
resolution 30% higher than those of the MEAP collimator,
whereas we used an ME collimator with a higher sensitivity
but a lower spatial resolution than the LEHR collimator.
With the FORTE camera, the sensitivity was improved by
1.35-fold from 4.6 cpm/kBq with the LEHR collimator to
6.2 cpm/kBq with the ME collimator, and the spatial
resolution was degraded from 7.4 to 11.3 mm in full width
at half maximum. With the DSX rectangular camera, the
changes were not as great as with the FORTE camera.
Second, they took no account of the differences in the
energy window. Third, they did not note the direction of the
star-shaped artifacts. Therefore, it is difficult to derive
common conclusions from these 2 studies. They reported
that the resolution advantage of the LEHR collimator over
the LEAP collimator was theoretically minimal over short
distances but that the lower sensitivity might lead to a
preference for the LEAP collimator. The optimization for
99mTc of all LE collimators also causes star-shaped artifacts
on LEHR collimator images. In contrast, Krynyckyi et al.
(17) reported that a small amount of star-shaped artifacts
could be eliminated by shifting the energy window upward
for 99mTc.
One means of reducing star-shaped artifacts is to reduce
the injection dose. However, this method is unfavorable
because it results in a decrease in the amount of radioac-
tivity that flows into the SLN and consequently decreases
lymph node detection. Therefore, some authors recommend
the use of a high-resolution collimator (8) or a super-high-
resolution collimator (7).
Evaluation of Image Contrast
The ME method showed high contrast at a distance of
more than 3 cm from the injection site. Because we con-
firmed from our clinical experience that the distance to
the SLNs was more than 3 cm, these results are considered
useful.
The results of the present study indicated that stable
contrast could be obtained after 4 min for the ME method,
indicating that 5 min would be sufficient in clinical use.
The results indicated that the ME method has significant
potential for shortening the acquisition time.
CONCLUSION
The first merit of the ME method is that there is no fear
that the lymph node will be concealed by a lead shield.
Moreover, improvement in the regional lymph node detec-
tion rate and shortening of the imaging time in breast
cancer patients can be expected with a shift in the energy
window.
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